Nonalcoholic Steatohepatitis and Endpoints in Clinical Trials.
Nonalcoholic fatty liver disease (NAFLD) is now the leading cause of liver disease in developed countries, and the rates of NAFLD continue to rise in conjunction with the obesity pandemic. While the majority of patients with isolated steatosis generally have a benign course, a diagnosis of nonalcoho...
| Published in: | Gastroenterology & Hepatology Vol. 12; no. 12; pp. 756 - 764 |
|---|---|
| Main Authors: | , , |
| Format: | tables/charts Journal Article |
| Published: |
Gastro-Hep Communications, Inc
Dec2016
|
| Online Access: | View this record in EBSCOhost |